October 14, 2009
By:
Dan Mendelson
As the health care reform debate continues to rage on Capitol Hill, pharma companies should be engaged in intense strategic planning for the future. Putting together a game plan now for the most likely reform scenarios will help companies to stay ahead of the curve.
|
January 1, 2007
By:
Jill Wechsler
The anticipated Congressional free-for-all on the Bush administration will put FDA officials in the hot seat. There will be hearings on inadequate oversight of drug safety, conflicts of interest, importation, and hasty approvals.
|
December 1, 2006
By:
Jill Wechsler
The Democrats are back in power in Congress, and they have their eyes on the drug industry. Look for hearings, investigations, an attack on the Medicare 'non-interference' clause, and a tough PDUFA reauthorization.
|
November 1, 2006
By:
Sarah Houlton
Pfizer says it is trying to stamp out counterfeiting by consolidating under one drug distributor. Critics think otherwise.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
